Several disubstituted-and deoxydisubstituted-derivatives of α-D-xylofuranose have been synthesized and evaluated on various in vitro human cancer cell lines. In primary in vitro screening, seven derivatives expressed anticancer activity.
Introduction
A large number of compounds with diverse chemical structure and molecular weight are reported to be effective anticancer agents. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Among them, several branched-chain sugar derivatives, [11] [12] [13] [14] [15] as well as some low molecular weight sugar derivatives with aminoalkyl appendages, [1] [2] [3] [4] have shown potent anticancer activity. In continuation of our efforts to find potent anticancer agents and on the basis of the correlation of anticancer activity in vitro, in vivo, and lipophilicity of the compounds of our previous work on aminoalkyl derivatives of sugars, 4, 16 we have synthesized disubstituted-and deoxydisubstituted-derivatives of α-D-xylofuranose and evaluated them for anticancer activity. 
Results and Discussion
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Pharmacological Evaluation
Several compounds were submitted to the National Cancer Institute (Bethesda, MD) for screening. For primary in vitro screening, compounds 7a-h and 9a-m were evaluated for their cytotoxic potency on three human cell lines (NCI-H460 lung cancer, MCF7 breast cancer and SF-268 CNS cancer). A compound is considered to be active when it reduces the growth of any of the cell lines to 32% or less. Among them, seven compounds (7a, 7b, 7c, 7f, 7g, 9c and 9h) were found active (concentration 10 -4 M) in primary screening. Details of this in vitro test method and the information, encoded by the activity pattern over all cell lines, have been previously reported. 18 Further investigation is in progress.
In summary, a series of disubstituted-and deoxydisubstituted-derivatives of α-Dxylofuranose was synthesized and evaluated for anticancer activity. The first results confirm the validity of our approach providing practical access to α-D-xylofuranose based derivatives possessing in vitro antiproliferative activity against human tumor cells. Evaluation of compounds 7a, 7b, 7c, 7f, 7g, 9c and 9h on a full panel of 60 human cancer cell lines is underway and the results will be disclosed in due course.
Experimental Section
General Procedures. Melting points were determined in open capillaries on a Büchi B-545 melting point apparatus. Compounds were routinely checked for their purity on silica gel 60 F 254 TLC plates and their spots were visualized by exposing them to iodine vapors or by charring the plates with 5% H 2 SO 4 -EtOH reagent or by spraying the plates with Dragendorff′s reagent. IR spectra were recorded on a Perkin-Elmer spectrum RX series FT-IR spectrophotometer.
1 H NMR spectra were recorded on a Bruker Advance DRX 200 MHz instrument as solutions (in CDCl 3 ) using TMS as internal reference, and chemical shifts values are expressed in δ units. Mass spectra were run on an Applied Biosystems API 3000 instrument using direct inlet system under positive ion electrospray ionization source. Elemental analyses were carried out with a Perkin Elmer 2400 analyzer and the values found were within ±0.4% of theoretical values. 
1,2:5,6-Di-O-isopropylidene-α-D-glucofuranose (1).
1,2:5,6-Di-O-isopropylidene-3-O-{3'-(hydroxy)propyl}-α-D-glucofuranose (2).
A mixture of compound 1 (49.9 g, 192 mmol), 3-chloro-1-propanol (19.9 g, 211 mmol) and NaOH (23.0 g, 576 mmol) was stirred at 110 o C for 8 h. After cooling to 25-30 o C, the reaction mixture was extracted with EtOAc (2×200 mL). The combined organic layers were washed with water (2×100 mL), brine (1×100 mL), dried (Na 2 SO 4 ) and filtered. The filtrate was concentrated under reduced pressure to yield the crude product, which was purified by column chromatography over silica gel (100-200 mesh) using EtOAc-hexane (5:95) as eluent to give 2 as a colorless, thick oil, yield 52.1 g (85% 
1,2:5,6-Di-O-isopropylidene-3-O-{3′-(decyloxy)propyl}-α-D-glucofuranose (3).
A mixture of compound 2 (50.0 g, 157.2 mmol), 1-bromodecane (38.2 g, 172.9 mmol) and NaOH (18.9 g, 471.6 mmol) was stirred at 110 o C for 8 h. After cooling to 25-30 o C, the reaction mixture was extracted with EtOAc (2×200 mL). The combined organic layers were washed with water (2×100 mL), brine (1×100 mL), dried (Na 2 SO 4 ) and filtered. The filtrate was concentrated under reduced pressure to yield the crude product, which was purified by column chromatography over silica gel (100-200 mesh) using EtOAc-hexane (5:95) as eluent to give 3 as a colorless, thick oil, yield 62.1 g (86%). After completion of the addition, stirring was continued at the same temperature for 6 h. The reaction mixture was neutralized with a saturated solution of Na 2 CO 3 (pH 9.0) and the compound was extracted with EtOAc (2×150 mL). The combined EtOAc extracts were washed with water (2×100 mL), brine (1×100 mL), dried (Na 2 SO 4 ) and filtered. The filtrate was concentrated under reduced pressure to give a crude product, which was purified by column chromatography over silica gel (100-200 mesh) using EtOAc-hexane (1:1) as eluent to give 4, yield 50.15 g (89%). was continued at the same temperature for 6 h. Ethanol (500 mL) was added to the reaction mixture and the precipitated salts were filtered off and washed with ethanol (1×50 mL). The filtrate was concentrated under reduced pressure and the residue was dissolved in EtOAc (100 mL), dried (Na 2 SO 4 ) and filtered. 
3-O-{3′-(Decyloxy)propyl}-1,2-O-isopropylidene-α-D-xylofuranose (6).
To a stirred solution of aldehyde 5 (38.0 g, 98.4 mmol) in absolute MeOH (150 mL) was added NaBH 4 (5.5 g, 147.6 mmol) in portions at 0 o C. After completion of the addition, the reaction mixture was stirred at the same temperature for 6 h. The excess NaBH 4 was then decomposed by addition of acetone (20 mL) and the resulting solution was concentrated under reduced pressure. The residue was dissolved in EtOAc (200 mL) and washed with brine (1×50 mL). The organic layer was dried (Na 2 SO 4 ), filtered and the filtrate was concentrated under reduced pressure to give 6 as a colorless thick oil, yield 34.1 g (89%). and then extracted with EtOAc (2×25 mL). The combined EtOAc layers were washed with water (1×25 mL), brine (1×25 mL), dried (Na 2 SO 4 ) and filtered. The filtrate was concentrated under reduced pressure to give 7a as a colorless, thick oil, which was purified by column chromatography over silica gel (100-200 mesh) using EtOAc-hexane (7:3) as eluent, yield 0.64 g (66% 3-O-{3′-(Decyloxy)propyl}-1,2-O-isopropylidene-5-O-{2′-(1-hexamethyleneimino)ethyl}-α-D-xylofuranose (7b) . Colorless 
3-O-{3′-(Decyloxy)propyl}-1,2-O-isopropylidene-5-O-{3′-(N′,N′-dimethylamino)propyl}-α-D-xylofuranose (7h
3-O-{3′-(Decyloxy)propyl}-1,2-O-isopropylidene-5-deoxy-5-(pyrrolidin-1-yl)-α-D-xylofuranose (9a). General procedure for the preparation of 9.
A mixture of compound 8 (1.0 g, 1.85 mmol) and pyrrolidine (1.0 mL) was heated at 70 o C for 6 h. The excess of pyrrolidine was removed under reduced pressure and the residue was dissolved in EtOAc (25 mL). The EtOAc layer was washed with a saturated solution of NaHCO 3 (1×20 mL), brine (2×10mL), dried (Na 2 SO 4 ) and filtered. The filtrate was concentrated under reduced pressure to give a crude product, which was purified by column chromatography over silica gel (100-200 mesh) using EtOAc-hexane (7:3) as eluent to give 9a as a colorless, thick oil, yield 0.60 g (74%). IR (neat): 3300, 3100, 2900, 2800, 1650, 1440, 1390, 1350, 1150 cm -1 . 
